Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
03/01/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 38.3k | $0.88 | $33.6k | | 03/01/2023 |
03/01/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 47.2k | $0.88 | $41.5k | | 03/01/2023 |
03/01/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 6.4k | $0.88 | $5.6k | | 03/01/2023 |
02/27/2023 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 38.6k | $0.81 | $31.4k | | 02/27/2023 |
06/14/2022 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Common Stock | 23.1k | $0.00 | $0 | | 06/14/2022 |
06/14/2022 | Zynerba Pharmaceuticals, Inc. | ZYNE | Sale | Common Stock | 53 | $1.01 | $53.5 | | 06/14/2022 |
06/14/2022 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 34.7k | $1.01 | $35k | | 06/14/2022 |
03/01/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 25k | $2.17 | $54.3k | | 02/28/2022 |
03/01/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 4.1k | $2.17 | $9k | | 02/28/2022 |
03/01/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 24.8k | $2.17 | $53.9k | | 02/28/2022 |
02/28/2022 | Akebia Therapeutics, Inc. | AKBA | Grant | Employee Stock Option (Right to buy) | 739.7k | $2.16 | $1.6M | | 02/28/2022 |
02/28/2022 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 293.1k | $0.00 | $0 | | 02/28/2022 |
02/28/2022 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 25.1k | $2.15 | $54k | | 02/28/2022 |
08/03/2021 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Common Stock | 5k | $0.00 | $0 | | 08/03/2021 |
08/03/2021 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 7.5k | $4.44 | $33.3k | | 08/03/2021 |
03/16/2021 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 39.5k | $0.00 | $0 | | 03/16/2021 |
03/01/2021 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 25.3k | $3.40 | $86k | | 02/26/2021 |
03/01/2021 | Akebia Therapeutics, Inc. | AKBA | Sale | Common Stock | 24.7k | $3.40 | $83.8k | | 02/26/2021 |
02/26/2021 | Akebia Therapeutics, Inc. | AKBA | Grant | Employee Stock Option (Right to buy) | 403.6k | $3.46 | $1.4M | | 02/26/2021 |
02/26/2021 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 237.4k | $0.00 | $0 | | 02/26/2021 |
06/10/2020 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 15k | $5.21 | $78.2k | | 06/10/2020 |
02/28/2020 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 237.4k | $0.00 | $0 | | 02/28/2020 |
02/28/2020 | Akebia Therapeutics, Inc. | AKBA | Grant | Stock Option (Right to buy) | 403.6k | $8.87 | $3.6M | | 02/28/2020 |
11/20/2019 | Akebia Therapeutics, Inc. | AKBA | Purchase | Common Stock | 50k | $3.44 | $172k | | 11/20/2019 |
06/11/2019 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 15k | $13.50 | $202.5k | | 06/11/2019 |
06/03/2019 | Akebia Therapeutics, Inc. | AKBA | Exercise | Employee Stock Option (Right to buy) | 287k | $0.47 | $134.9k | | 06/03/2019 |
12/12/2018 | Akebia Therapeutics, Inc. | AKBA | Other (acquisition) | Common Stock | 1.2k | $0.00 | $0 | | 12/12/2018 |
12/12/2018 | Akebia Therapeutics, Inc. | AKBA | Payment of Exercise | Common Stock | 135.7k | $8.94 | $1.2M | | 12/12/2018 |
08/22/2018 | Zynerba Pharmaceuticals, Inc. | ZYNE | Purchase | Common Stock | 5k | $6.43 | $32.2k | | 08/22/2018 |
07/11/2018 | Akebia Therapeutics, Inc. | AKBA | Exercise | Employee Stock Option (Right to buy) | 100k | $0.47 | $47k | | 07/11/2018 |
06/06/2018 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 15k | $11.30 | $169.5k | | 06/06/2018 |
04/12/2018 | Zynerba Pharmaceuticals, Inc. | ZYNE | Grant | Stock Option (right to buy) | 35k | $9.90 | $346.5k | | 04/12/2018 |
02/28/2018 | Akebia Therapeutics, Inc. | AKBA | Grant | Common Stock | 88.9k | $0.00 | $0 | | 02/28/2018 |
02/28/2018 | Akebia Therapeutics, Inc. | AKBA | Grant | Employee Stock Option (Right to buy) | 126.3k | $14.30 | $1.8M | | 02/28/2018 |
06/09/2017 | KERYX BIOPHARMACEUTICALS INC | KERX | Grant | Stock Options (right to buy) | 30k | $6.56 | $196.8k | | 06/09/2017 |
|